Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancerNanwei Xu(Sichuan University), Hao Zeng(Sichuan University)Journal of Cancer Research and Clinical OncologyMarch 13, 202310.1007/s00432-023-04639-9Cited by 6SaveCiteExport RISWatch citationsRelated PapersDifferential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma|BMC Cancer|2019|25Efficacy of Second-Line ICIs Combined with TKIs among Patients with Metastatic Renal Cell Carcinoma: A Real-World Study|Immunotherapy|2022|2